CompletedNCT02435654
5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
Medication studyAges 7–17China
Understand this study
Who was this study for?
Listed age limits: 7 years to 17 years.
What did participation involve?
The study group receives olanzapine as a study medication.
- Listed locations
- KunmingSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: August 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 128
- Sponsor
- Kunming Medical University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- China
- Age range
- From 7 Years to 17 Years
- Official registry ID
- NCT02435654
- Official title
Show the full official title
Effects of 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Drug Plasma Concentration on Antipsychotic Response to Olanzapine in Treatment of Early-onset Schizophrenia
Recruitment & locations
CompletedKunming
Questions about this study
Who is behind this study?
The study sponsor is Kunming Medical University, a university.
Did this study involve medication?
Yes. The study involved medication, including olanzapine.
Who was this study for?
Listed age limits: 7 years to 17 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolarity
A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia